银丹心脑通结合阿托伐他汀治疗稳定型心绞痛的效果及安全性  

Efficacy and safety of Yindan Xinnaotong capsule combined with atorvastatin in patients with stable angina pectoris

作　　者：李欣星 李奎 康妮娜 张倩 Li Xin-xing;Li Kui;Kang Ni-na;Zhang Qian(Department of Cardiovascular Medicine,Yibin Third People’s Hospital,Yibin 644000,China;Department of Cardiovascular Medicine,Yibin First People's Hospital,Yibin 644000,China)

机构地区：[1]宜宾市第三人民医院心血管内科,宜宾644000 [2]宜宾市第一人民医院心血管内科,宜宾644000

出　　处：《中国药物应用与监测》2024年第6期821-825,共5页Chinese Journal of Drug Application and Monitoring

摘　　要：目的探究银丹心脑通软胶囊联合阿托伐他汀治疗稳定型心绞痛(SAP)的效果及其安全性。方法纳入2022年2月至2024年2月宜宾市第三人民医院SAP患者为研究对象,采用信封法随机分配进入研究组和对照组,各完成临床观察59例。两组均给予常规治疗,对照组给予阿托伐他汀治疗,研究组在对照组基础上增加银丹心脑通软胶囊治疗,比较两组治疗6周后临床疗效,治疗前后心绞痛发作次数和持续时间、心功能[左室射血分数(LVEF)、左室收缩末期内径(LVESD)、左室舒张末期内径(LVEDD)、心搏出量(SV)及心脏指数(CI)]、血脂、血清生化指标[C反应蛋白(CRP)、中性粒细胞与淋巴细胞比值(NLR)、脑尿钠肽(BNP)]水平变化及不良反应。结果研究组临床总有效率为94.92%(56/59),高于对照组的83.05%(49/59)(χ^(2)=4.236,P<0.05);治疗6周后,对照组和研究组心绞痛发作次数和持续时间[分别是(3.44±0.49)次·周^(-1)、(4.46±0.57)次·周^(-1)、(2.72±0.37)min·次^(-1)、(3.31±0.44)min·次^(-1)],高于治疗前[分别是(6.52±0.71)次·周^(-1)、(6.34±0.65)次·周^(-1)、(5.32±0.65)min·次^(-1)、(5.49±0.74)min·次^(-1),且研究组低于对照组(P<0.05)];治疗后,对照组和研究组LVEF、SV、CI水平[分别是(58.37±4.67)%、(54.37±5.03)%、(73.48±7.13)mL、(70.22±6.18)mL、(4.67±0.23)L·(min·m^(2))^(-1)、(4.11±0.31)L·(min·m^(2))^(-1)],高于治疗前[分别是(48.61±3.12)%、(49.14±3.27)%、(63.72±6.31)mL、(64.13±5.66)mL、(2.41±0.61)L·(min·m^(2))^(-1)、(2.48±0.42)L·(min·m^(2))^(-1)],差异有统计学意义(P均<0.05),LVESD、LVEDD[分别是(34.37±2.63)mm、(39.56±3.11)mm、(51.37±4.39)mm、(56.38±4.51)mm],低于治疗前[分别是(46.21±3.47)mm、(45.87±3.22)mm、(62.19±5.22)mm、(61.76±5.37)mm],差异有统计学意义(P均<0.05),且研究组LVEF、SV、CI水平高于对照组(P均<0.05),LVESD、LVEDD水平低于对照组(P均<0.05);治疗后,对照组和研究组血清TC、TG、LDL-C水平Objective To explore the efficacy and safety of Yindan Xinnaotong soft capsule combined with atorvastatin in treatment of stable angina pectoris(SAP).Methods A total of 118 patients with SAP admitted to Yibin Third People’s Hospital from February 2022 to February 2024 were selected as the research subjects and divided into the study group(treated with Yindan Xinnaotong)and the control group(treated with atorvastatin)according to the envelope method,with 59 in each group.All the patients in both groups were given conventional treatment.The patients in the control group received atorvastatin treatment while those in the study group were treated with Yindan Xinnaotong soft capsule based on the regimen in the control.The clinical efficacy 6 weeks after treatment,frequency and duration of angina pectoris attack,cardiac function(left ventricular ejection fraction(LVEF),left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD),stroke volume(SV),cardiac index(CI)),blood lipids and serum biochemical indicators(C-reactive protein(CRP),neutrophil-to-lymphocyte ratio(NLR),brain natriuretic peptide(BNP))before and after treatment and adverse reactions were compared between the two groups.Results The total clinical effective rate was 94.92%(56/59)in the study group,which was higher than that of 83.05%(49/59)in the study group(χ^(2)=4.236,P<0.05).After treatment for 6 weeks,the frequency and duration of angina pectoris attack in the two groups were((3.44±0.49)times/week,(4.46±0.57)times/week,(2.72±0.37)min/time,(3.31±0.44)min/time,which were higher than those before treatment(6.52±0.71)times/week,(6.34±0.65)times/week,(5.32±0.65)min/time,(5.49±0.74)min time)and they were significantly lower in the study group than in the control(P<0.05).After treatment,LVEF,SV and CI in the two groups were(58.37±4.67)%,(54.37±5.03)%,(73.48±7.13)mL,(70.22±6.18)mL,(4.67±0.23)L·(min·m^(2))^(-1),(4.11±0.31)L·(min·m^(2))^(-1),which were higher than thsoe of(48.61±3.12)%,(49.14±3.27)%,(63.72±

关 键 词：银丹心脑通软胶囊 阿托伐他汀 稳定型心绞痛 临床疗效 血脂 心功能 

分 类 号：R541.4[医药卫生—心血管疾病]